Tempus AI has acquired Paige, a pioneer in AI-powered digital pathology, in a deal valued at $81.25 million. The transaction will be paid predominantly in Tempus stock and includes the assumption of Paige’s remaining obligations under its Microsoft Azure cloud services agreement.
Founded in 2017, Paige has developed several groundbreaking applications, including the first FDA-cleared AI tool in pathology to help pathologists and researchers detect cancer more accurately. The company has built one of the most comprehensive digital pathology datasets in the world through its relationship with Memorial Sloan Kettering Cancer Center, encompassing nearly 7 million digitized slides paired with clinical and molecular data. All data has been de-identified to protect patient privacy and represents patients from 45 countries across diverse populations.
In addition to its dataset, Paige has developed a million-slide foundation model for cancer and most recently introduced PRISM2, an AI platform created with Microsoft Research. PRISM2 links visual tissue patterns with clinical language, enabling large-language models to interpret pathology data for use in diagnostics, biomarker discovery, drug development, and outcome prediction.
The acquisition builds on Tempus’ own AI ambitions, including its $200 million partnership with AstraZeneca and Pathos AI to create a multimodal foundation model for oncology.
“As we embark upon building the largest foundation model ever created in oncology, the acquisition of Paige substantially accelerates our efforts,” said Eric Lefkofsky, Founder and CEO of Tempus. “Paige is a leader in digital pathology and has amassed one of the most comprehensive datasets in the world. Their team’s expertise in generative AI and the scale of their data will be catalytic across all of our AI efforts.”
Paige’s CEO and CTO, Razik Yousfi, said the move expands the reach of its innovations: “We’ve always believed the future of cancer care and precision medicine lies in harnessing AI to transform how cancer is detected, understood, and treated. By joining forces with Tempus, we can bring our technologies to a broader patient population and deliver even greater impact.”
With the acquisition, Tempus strengthens its position at the intersection of AI, oncology, and digital pathology, combining Paige’s cutting-edge platforms and datasets with its own precision medicine ecosystem to accelerate advancements in cancer research and treatment.
Click here to read the original news story.